Puma Biotechnology Inc (NYSE:PBYI) had its price objective boosted by Citigroup Inc. from $156.00 to $164.00 in a report published on Friday, Marketbeat reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Several other research analysts have also issued reports on the company. Royal Bank Of Canada decreased their target price on Puma Biotechnology from $108.00 to $92.00 and set a sector perform rating for the company in a research report on Friday. They noted that the move was a valuation call. Leerink Swann increased their target price on Puma Biotechnology to $140.00 and gave the stock an outperform rating in a research report on Friday, October 27th. Bank of America Corporation reissued a buy rating and issued a $135.00 target price (up previously from $117.00) on shares of Puma Biotechnology in a research report on Monday, October 9th. J P Morgan Chase & Co reissued a buy rating and issued a $131.00 target price on shares of Puma Biotechnology in a research report on Wednesday, October 4th. Finally, BidaskClub raised Puma Biotechnology from a buy rating to a strong-buy rating in a research report on Tuesday, October 3rd. One analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the stock. Puma Biotechnology currently has a consensus rating of Buy and an average price target of $130.67.
Shares of Puma Biotechnology (NYSE:PBYI) traded down $1.90 during trading hours on Friday, hitting $101.10. The stock had a trading volume of 1,681,600 shares, compared to its average volume of 1,121,087. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90.
Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same period in the prior year, the company posted ($1.11) EPS.
COPYRIGHT VIOLATION WARNING: This piece was first published by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.thestockobserver.com/2017/11/14/citigroup-inc-raises-puma-biotechnology-inc-pbyi-price-target-to-164-00.html.
In other Puma Biotechnology news, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $100.09, for a total transaction of $1,501,350.00. Following the sale, the senior vice president now directly owns 28,239 shares in the company, valued at approximately $2,826,441.51. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 22.70% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the company. Strs Ohio purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $122,000. Cubist Systematic Strategies LLC purchased a new position in shares of Puma Biotechnology in the 2nd quarter worth $146,000. Kazazian Asset Management LLC bought a new position in Puma Biotechnology in the 2nd quarter worth $209,000. Teacher Retirement System of Texas bought a new position in Puma Biotechnology in the 2nd quarter worth $211,000. Finally, Ameritas Investment Partners Inc. raised its holdings in Puma Biotechnology by 5.9% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock worth $220,000 after purchasing an additional 140 shares during the period. Hedge funds and other institutional investors own 80.98% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.